Sonoma pharmaceuticals reports fiscal year and fourth quarter 2023 financial results

Revenues increased 31% in q4 2023 compared to q4 2022 revenues increased 5% in fy 2023 compared to fy 2022 net loss improved 56% quarter over quarter net loss minus non-cash and one-time expenses decreased 65% quarter over quarter and 26% year over year boulder, co / accesswire / june 22, 2023 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing patented microcyn® technology-based stabilized hypochlorous acid (hocl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2023 and the fourth quarter ended march 31, 2023. "our increased revenues and shrinking losses reflect the strength of our growing and diversified business, both geographically and in our product portfolio.
SNOA Ratings Summary
SNOA Quant Ranking